key: cord-0075950-orl2il9z
authors: Flume, Patrick A.
title: From the Editor's Desk
date: 2022-03-22
journal: J Cyst Fibros
DOI: 10.1016/j.jcf.2022.03.003
sha: 8b233bfccace13b0a575b8984e0def608980fd06
doc_id: 75950
cord_uid: orl2il9z

nan

Another year has passed and the pandemic is still upon us. The CF community has demonstrated considerable innovation and resiliency in response to the threat of the novel coronavirus (SARS-CoV-2). I remain highly impressed at how the international CF community came together to share data as we learned about this virus [1] . Clinical care and research were disrupted [2] , but we adapted, and those novel approaches to provision of care were shared in our pages. The delivery of care will be forever changed, mostly because of technology but the pandemic was the accelerant. This was described in greater detail in a supplement dedicated to the topic of the future of CF care [3] and we will need to continue to innovate, testing new methods in order to achieve the best for those we serve.

Despite the surges of the pandemic, the Journal of Cystic Fibrosis (JCF) and other journals continued to receive a large number of high quality CF-specific manuscripts, demonstrating that scholarly activities would not be denied. We include in this issue a review of CF highlights from the past year [4] to offer but a glimpse of some of the recent major advances in our knowledge. A testament to the high quality of manuscripts submitted to JCF is that we published more articles than any previous year and still had an increase in impact factor. The recently published papers with the greatest number of citations in 2021 are shown in Table 1 . An Table 1 Top Ten Recent Manuscripts Cited in 2021.

Type * Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries [5] Original article * A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis [6] Original article * CFTR modulator theratyping: Current status, gaps and future directions [7] Review * Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease [8] Original article * Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines [9] Review * The global impact of SARS-CoV-2 in 181 people with cystic fibrosis [10] Original article * An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5?years (KLIMB) [11] Original article * Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis [12] Review * Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection [13] Original article * Predictive factors for lumacaftor/ivacaftor clinical response [14] Original article * Open Access important observation is that all of these papers are available as Open Access, freely available to all readers. We appreciate that our publisher has worked with countries and institutions to enable authors to publish in this manner, with an increase in Open Access articles by > 300 percent. As I have stated before, we do not assess our success by citations alone; our readership includes all members of the multidisciplinary team, persons with CF, and their families. They access JCF through downloads and social media citations, and downloads increased by more than 7% from the previous year.

We remain grateful to the Editorial Board and reviewers who contribute to the peer review processes so vital to JCF. They help us identify and improve the manuscripts that eventually find their way into JCF. We know that the editorial review process places great burden on the editors and reviewers. The editorial board is listed in the masthead of the journal and we include a complete list of all who performed at least one review for JCF in this issue [189-378]. Those individuals who performed at least five reviews are listed in Table 2 , but we especially want to recognize Pierre-Regis Burgel (16), Bradley Quon (15), Jenna Sykes (9), Frank Bodewes (9), and Anne Stephenson (9) as our top five reviewers of 2021. Table 2 Individuals who performed ≥5 reviews during 2021.

Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: an international observational study

The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network

Impact of the COVID-19 Pandemic: how our response is shaping the future of cystic fibrosis care

A year in review: real world evidence, functional monitoring and emerging therapeutic strategies in 2021

Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries

A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis

CFTR modulator theratyping: Current status, gaps and future directions

Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease

Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines

The global impact of SARS-CoV-2 in 181 people with cystic fibrosis

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB)

Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis

Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection

Predictive factors for lumacaftor/ivacaftor clinical response